SNPMiner Trials (Home Page)
Report for Mutation N409S
Developed by Shray Alag, 2020.
SNP Clinical Trial Gene
There is one clinical trial.
Clinical Trials
1 A Multicenter, Safety and Efficacy Study of Taliglucerase Alfa in Subjects With Type 3 Gaucher Disease
This is a multicenter study to assess the safety and efficacy of taliglucerase alfa (60 units/kg) in previously untreated subjects of any age with Type 3 GD. Subjects will receive an infusion of taliglucerase alfa every 2 weeks for 12 months. Subjects who tolerate the infusions well, and who are treated in centers where home therapy is the SOC will be allowed to switch from site to home treatment at the discretion of the PI but after no less than 3 uneventful infusions at the site.
NCT04002830 Gaucher Disease, Type 3 Drug: Elelyso MeSH:Gaucher Disease
At least one allele of: - N370S (N409S in recent nomenclature) - R496H (R535H in recent nomenclature) 4. Presence of calcification in heart valves or arteries in echocardiography. 5. Presence of untreated iron, folic acid, vitamin B12 deficiency and/or hypothyroidism. --- N370S --- --- N409S ---
Primary Outcomes
Description: Percent change from baseline
Measure: Percent change from baseline in spleen volume measured by MRI Time: from baseline to month 12Secondary Outcomes
Description: Percent change from baseline
Measure: Percent change from baseline in liver volume measured by MRI Time: from baseline to month 12Description: Percent change from baseline
Measure: Percent change in hemoglobin Time: from baseline to Months 3, 6, 9, and 12Description: Percent change from baseline
Measure: Percent change in platelet count Time: from baseline to Months 3, 6, 9, and 12Description: Percent change from baseline
Measure: Percent change in Lyso-GB1 Time: from baseline to Months 3, 6, 9, and 12